This differential flexibility between MAPK1 (more rigid) and ADRA2A (more flexible) suggests distinct pharmacological behaviors, collectively contributing to ACP’s potential multi-target, combinatorial effects in addressing various facets of allergic diseases, from immune modulation to symptom alleviation. This evidence concerns the gene ADRA2A and allergic disease.